[III-JCKAP7-2-6] Mid-Term Outcome of Pulsta valve for Percutaneous Pulmonary Valve Implantation in The Native Right Ventricular Outflow Tract Dysfunction
Keywords:RVOT dysfunction , PPVI , self-expandable pulmonary valve
Background PPVI is a good treatment for RVOT dysfunction. This study reports the clinical use in various morphology of RVOT and mid-term outcome of a novel transcatheter self-expandable pulmonary valve (Pulsta valve) in native RVOT dysfunction. Methods A total of 43 patients who underwent PPVI with Pulsta valve in a single center from December 2017to May 2022 were enrolled. Patients' demographics and pre-, intra- and post-procedure follow-up data were collected and analyzed. Results The most of patients were female (n=27), with a mean age of 27.0 years and a mean weight 61.0kg. 38 of 43 Patients showed moderate to severe PR, with a mean PR fraction derived cardiac MRI of 40.7%. The procedure success rate was 97.6 % with a mean fluoroscopy time of 25.0 min and mean procedure time of 103.2 min. Valve sizes used were 26 (n=3), 28 (n=13), 30 (n=7), 32 (n= 15), and 33.5 (n=5). Procedural complications were arrhythmia requiring treatment (n=2), delivery catheter associated complication (n=1), device embolization (n=1). 1-year follow-up cardiac MRI showed a decreased PR fraction (14.5%) and that the right ventricular end-diastolic volume index decreased from 153.2 to 120.3 mL/m2, the right ventricular end-systolic volume index decreased from 81.3 to 62.4 mL/m2. There was no significant PR and PS overtime. There was no mortality, or re-intervention during follow-up. And no patients had more than mild PR and paravalvular leakage. Conclusions PULSTA valve provides excellent mid-term outcomes in patients with the various morphology of RVOT and special situation in high risk patients